Vivos Therapeutics Inc expected to post a loss of 26  cents a share - Earnings Preview

Vivos Therapeutics

13/05/2022 23:16

* Vivos Therapeutics Inc  VVOS.OQ   VVOS.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 16. 
    * The Highlands Ranch Colorado-based  company is expected to
report  a 28.8% increase in revenue to $4.442 million from $3.45
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Vivos Therapeutics
Inc is
for a loss of 26 cents per share. For the same quarter last
year, the company reported a loss of 19 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vivos
Therapeutics Inc is $9​, above​ its last closing price of $1.39.
​​​

This summary was machine generated May 13 at 22:15 GMT.  All
figures in US dollars  unless otherwise stated